New targets of treatment of patient from the risk group for vascular complications of atherosclerosis


Cite item

Full Text

Abstract

Based on the results of recent studies of statins (JUPITER, etc.) discussed the potential positive therapeutic effects (anti-inflammatory, antithrombotic) of this group medicine that could be grounds for revision of guidance for their use. Emphasized the importance of the statins impact on C-reactive protein (CRP), given the fact that the latter is an active participant in atherothrombosis. We showed that the relatively healthy people with high CRP levels treated with active statin, had not only myocardial infarction or stroke risk reduction, but also frequency reduction of thromboembolic complications and death from cancer. The author believes that the statins administration in the normalization of CRP should be another factor tracked during treatment, in addition to the level of low density lipoprotein.

References

  1. Jialal I, Devaraj S, Venugopal SK. C-Reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004;44(1):6-11.
  2. Ridker PM, Rifai N, Pfeffer A, et al. Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels. Circulation 1998;98:839-44.
  3. Mannacio VA, Iorio D, De Amicis V, et al. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: A randomized trial. J Thorac Cardiovasc Surg 2008;136:1541-48.
  4. Sasaki J, Iwashita M, Kono S. Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb 2006;13(3):123-29.
  5. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59.
  6. Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J 2003;24:225-48.
  7. Heeschen С, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rats in patients with acute coronary syndromes. Circulation 2002;105:1446-52.
  8. Glynn RJ, Danielson E, Fonseca FAH, et al. A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. N Engl J Med 2009;360:1851-61.
  9. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373(9670):1175-82.
  10. Michos ED, Blumenthal RS. Prevalence of Low Low-Density Lipoprotein Cholesterol With Elevated High Sensitivity C-Reactive Protein in the U.S.: Implications of theJUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) Study. J Am Coll Cardiol 2009;53:931-35.
  11. http://www.pharmateca.ru/cgi-bin/magazine.pl?magid=174&mid=1085056570

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies